- FUJIFILM Biotechnologies has opened its $3.2 billion commercial-scale manufacturing site in Holly Springs, North Carolina, equipped with 8 x 20,000 L bioreactors.
- The site currently employs over 680 staff, with plans to reach 1,400 employees by 2031.
FUJIFILM Biotechnologies has officially opened its new manufacturing site in Holly Springs, North Carolina, marking the first phase of a planned $3.2 billion investment. The facility is one of the largest commercial-scale cell culture biomanufacturing sites in North America.
The new site opens with a capacity of 8 x 20,000 litre mammalian cell culture bioreactors to produce both drug substance and drug product. Finished goods capabilities are scheduled to be added in 2026. A second phase, announced in 2024, will double capacity with a further 8 bioreactors, bringing the total to 16.
“Our new commercial-scale manufacturing hub in the U.S. highlights Fujifilm’s dedication to supporting our partners in delivering biologic medicines targeting complex diseases.”
Toshihisa Iida, director, corporate vice president, and chairman of FUJIFILM Biotechnologies
Local and state officials joined the company to celebrate the opening, including North Carolina Governor Josh Stein, who said the facility will generate 1,400 new jobs by 2031 and add $4.7 billion to the state’s economy over the next decade. The site currently employs more than 680 people and expects to reach 750 by the end of 2025.
Designed with sustainability in mind, the Holly Springs facility will offset 100% of carbon emissions from electricity consumption through renewable energy certificates. This initiative supports FUJIFILM’s broader target of achieving carbon neutrality by the end of fiscal year 2040.
